In sharp contrast to earlier studies, patients with severe triple-vessel heart disease fared equally well whether they ...

Qualigen and Marizyme have entered an MOU dated March 28, 2025. This is the logical next step in acquiring Marizyme, following on our co-marketing agreement established in 2024. Upon completion of ...

The following is a summary of "Transit time flow management as a management strategy in high-risk groups undergoing coronary ...

Cotemporary DES paired with FFR guidance and modern medical therapy may be what narrowed the gap, William Fearon says.

Compared with other studies, the differences in outcomes between percutaneous coronary intervention (PCI) and coronary artery ...